BLC
RPRX icon

Brown, Lisle/Cummings’s Royalty Pharma RPRX Stock Holding History

Brown, Lisle/Cummings’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.58K Sell
153
-64
-29% -$3.33K ﹤0.01% 623
2026
Q1 		$10.4K Buy
+217
New +$9.5K ﹤0.01% 569

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown, Lisle/Cummings's RPRX Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Royalty Pharma (RPRX) stake by 29% in Q2 2026, selling an estimated $3.33K and leaving 153 shares worth $8.58K. The position accounts for ﹤0.01% of the portfolio, ranked #623.

Brown, Lisle/Cummings first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $10.4K in Q1 2026. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Brown, Lisle/Cummings held 153 shares of Royalty Pharma worth $8.58K as of Q2 2026.
  • Brown, Lisle/Cummings sold 64 Royalty Pharma shares in Q2 2026, an estimated $3.33K.
  • Royalty Pharma made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #623 holding.
  • Brown, Lisle/Cummings first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • Brown, Lisle/Cummings's Royalty Pharma position peaked at $10.4K in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.